Xellia Pharmaceuticals AS

Generics maker Hikma will shell out up to $185 million to acquire parts of Xellia’s assets in the U.S., including the Danish drugmaker’s 24-acre manufacturing facility in Cleveland. Hikma, a London-based generics maker, has agreed to buy parts of Xellia’s assets in the U.S., including the Danish drugmaker’s manufacturing facility in Cleveland. Hikma will pay $135 million in cash with an additional $50 million going to Xellia based on contingencies, the company said in a June 17 press release. The deal is subject to approval from the U.S. Federal Trade Commission. Under terms of the transaction, Hikma gets the Cleveland facility that features end-to-end capabilities to develop, manufacture, pack and distribute lyophilized vials and aseptically filled ready-to-use IV bag products. The generic drugmaker revealed plans to invest an undisclosed amount into the facility to boost productivity by adding automation, equipment and updated processes. Hikma aims to complete the upgrades at the plant within the next three years. The facility could be used to establish an entry into the CDMO business in the future, the company said. “Hikma has grown to become a top-three U.S. supplier of sterile injectable medicines thanks to our strong record of successfully making value-enhancing acquisitions like this one,” Riad Mishlawi, Hikma’s chief executive, said in the release. “This acquisition will add significant scale to our U.S. operations and will enhance our U.S. injectable manufacturing capabilities and portfolio by adding complex technologies.” Hikma also gets a range of ready-to-use products from Xellia, including Vanco Ready (vancomycin) used to treat bacterial infections like methicillin-resistant Staphylococcus aureus (MRSA). Additionally, it picks up an R&D facility and its staff located in Zagreb, Croatia, with the deal. In 2022, Hikma entered the Canadian market with the $45.75 million purchase of assets of Taligent, which was under bankruptcy. That deal included 25 sterile injectable products, three in-licensed ophthalmic products and seven other products (four of them approved by Health Canada) that were in Teligent’s pipeline at the time.

MENLO PARK, Calif.--(BUSINESS WIRE)-- ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced the appointment of Dean J. Mitchell as chairman of its Board of Directors. Mr. Mitchell is a highly experienced and well-regarded biotechnology and pharmaceutical industry veteran who brings over three decades of experience as a board director and corporate executive to the ReCode board. “We are delighted to have Dean join the board as we continue to advance our respiratory clinical development programs and leverage our novel SORT LNP delivery platform to expand our portfolio,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics. “His proven track record at growing and scaling biopharma companies is a welcome addition to our board that will support the company’s near- and long-term growth.” “I am pleased to join the talented ReCode board at a pivotal time for the company as it continues to achieve significant milestones for its lead clinical programs and expand its research and discovery efforts into gene correction,” said Mr. Mitchell. “I look forward to working with the board and the executive team to advance these novel therapies with the goal of one day providing much-needed treatments for patients living with rare diseases.” Mr. Mitchell currently serves as chairman of the Board of Directors of Praxis Precision Medicines, Inc., an appointment he has held since 2020, and as a board director for Theravance Biopharma, Inc. (since 2014) and Precigen (since 2009). Mr. Mitchell previously served as board chairman of Kinnate Biopharma, Inc. until its sale in 2024 and as board director for ImmunoGen, Inc. until its sale in 2024. He served as executive board chairman for Covis Pharma Holdings until its sale in 2020 and board chairman of PaxVax Corporation until its sale in 2018. Mr. Mitchell previously held the position of president and chief executive officer at Lux Biosciences, Inc., a biotechnology company focusing on the treatment of ophthalmic diseases, at Alpharma, Inc., a publicly traded specialty pharmaceutical company until its acquisition by King Pharmaceuticals, Inc., and at Guilford Pharmaceuticals, Inc., a publicly traded pharmaceutical company focused on oncology and acute care, until its acquisition by MGI Pharma Inc. He previously held executive roles at Bristol Myers Squibb and GlaxoSmithKline. Mr. Mitchell earned a B.A. from City University London and a B.Sc. in biology from Coventry University. About ReCode Therapeutics ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues, and cells implicated in disease, enabling improved efficacy and potency. ReCode’s lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13% of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases, including musculoskeletal, central nervous system, liver, and infectious disease indications. ReCode has been recognized by the San Francisco Business Times and Silicon Valley Business Journal as a Best Place to Work. For more information, visit and follow us on LinkedIn and Instagram.

DUBLIN, March 7, 2024 /PRNewswire/ -- The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering. Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. Fully revised and updated, the report provides details of co-promotion and co-marketing deals from 2016 to 2024, the report provides access to co-promotion and co-marketing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of co-promotion and co-marketing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of co-promotion and co-marketing deals. Chapter 4 provides a review of the leading co-promotion and co-marketing deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive listing of the top 25 most active co-promotion and co-marketing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. Chapter 6 provides a comprehensive and detailed review of co-promotion and co-marketing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-promotion and co-marketing deal. The deal directory includes a comprehensive listing of all co-promotion and co-marketing deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document. The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing alliances. Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits: Understand deal trends since 2016 Browse co-promotion and co-marketing deals Benchmark analysis - identify market value of transactions Financials terms Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology includes: Trends in co-promotion and co-marketing dealmaking in the biopharma industry Overview of co-promotion and co-marketing deal structure Directory of co-promotion and co-marketing deal records covering pharmaceutical and biotechnology The leading co-promotion and co-marketing deals by value Most active co-promotion and co-marketing dealmakers The leading co-promotion and co-marketing partnering resources Analyzing contract agreements allows due diligence of: What are the rights granted or optioned? What rights are granted by the agreement? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are intellectual property rights handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in co-promotion and co-marketing dealmaking 2.1. Introduction 2.2. Definition of co-promotion and co-marketing deals 2.3. Trends in co-promotion and co-marketing deals since 2016 2.3.1. Co-promotion and co-marketing dealmaking by year, 2016-2024 2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2016-2024 2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2016-2024 2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2016-2024 2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2016-2024 2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2016-2024 2.4. Reasons for entering into co-promotion and co-marketing partnering deals 2.5. The future of co-promotion and co-marketing deals Chapter 3 - Overview of co-promotion and co-marketing deal structure 3.1. Introduction 3.2. Co-promotion and co-marketing agreement structure Chapter 4 - Leading co-promotion and co-marketing deals 4.1. Introduction 4.2. Top co-promotion and co-marketing deals by value Chapter 5 - Top 25 most active co-promotion and co-marketing dealmakers 5.1. Introduction 5.2. Top 25 most active co-promotion and co-marketing dealmakers Chapter 6 - Co-promotion and co-marketing deals including contracts directory 6.1. Introduction 6.2. Co-promotion and co-marketing deals with contracts 2016-2024 Deal directory Deal directory - Co-promotion and co-marketing dealmaking by companies A-Z Deal directory - Co-promotion and co-marketing dealmaking by therapy area Deal directory - Co-promotion and co-marketing dealmaking by technology type Some of the companies featured 3D Medicines 4D Molecular Therapeutics Abbvie AbCellera Biologics ALK-Abello Allegis Pharmaceuticals Allergan Bausch & Lomb Baxalta Bayer Beam Therapeutics BeiGene Beijing Minhai Biotechnology Belharra Therapeutics Belintra Berlin Chemie BioAge Labs Biogen Biognosys Biological Industries BioNano Genomics BioNTech Cipher Pharmaceuticals Concordia Pharmaceuticals CRISPR Therapeutics CrossLink Bioscience CSL Dova Pharmaceuticals Dovetail Genomics DualityBio Eagle Genomics Eagle Pharmaceuticals EA Pharma Eli Lilly Empatica Enterome Bioscience Epizyme Eton Pharmaceuticals Exact Sciences Fabric Genomics Gilead Sciences Glenmark Pharmaceuticals Goldfinch Bio GSK GT Research H3 Biomedicine Halyard Health Hanmi Pharmaceutical Harbin Pharmaceutical Group HD Biosciences Iconic Therapeutics Idorsia IGM Biosciences Illumina Immatics Biotechnologies Immunicon ImmunityBio Ionis Pharmaceuticals Ironwood Pharmaceuticals iTeos Therapeutics Janssen Biotech Janssen Pharmaceuticals Jiangsu Alphamab Konica Minolta Kowa Pharmaceuticals America KSQ Therapeutics Kyorin Pharmaceutical Kyowa Hakko Kirin Kyverna Therapeutics Luqa Pharmaceuticals Luxcel Biosciences Lygos Macrogenics Manchester BIOGEL MannKind Biopharmaceuticals Medicines360 MedImmune Medovate MEI Pharma Menarini Merck and Co Merck KGaA Mersana Therapeutics Mesoblast Metagenomi Metavant Microsoft Nkarta Therapeutics Novartis Novo Nordisk nRichDX Numab Otonomy Otsuka Oxford BioMedica Pacira Biosciences Paragon Bioservices Pfizer Phil Prothena Provention Bio PSI (Population Services International) Purdue Pharma Pure Pharmaceuticals QED Therapeutics Qiagen Quanta Radius Health Rainbow Scientific Rakuten Medical Recludix Pharma RedHill Biopharma RefleXion Medical Regeneron Pharmaceuticals Regenxbio Relay Therapeutics Repare Therapeutics Resonant Specific Technologies Revolution Medicines Rigel Pharmaceuticals Roche Sanofi Seren Pharmaceuticals Seres Therapeutics Shimadzu Shionogi Silicon Biosystems Simcere Pharmaceuticals Sirtex Medical SK Biopharmaceuticals Solid Biosciences Sonoma BioTherapeutics Sosei SparingVision Stealth BioTherapeutics Stoke Therapeutics StrideBio Tango Therapeutics Teijin Telix Pharmaceuticals Terumo Blood and Cell Technologies Tetraphase Pharmaceuticals Teva Pharmaceutical Industries Theravance Thermo Fisher Scientific Tilak Healthcare Tilray Titan Pharmaceuticals Tolmar Urovant Sciences US WorldMeds Verity Pharmaceuticals Vertex Pharmaceuticals Vertice Pharma Vifor Pharma Voyager Therapeutics WAVE Life Sciences Xellia Pharmaceuticals Xencor ZAI Laboratory Zymeworks For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets